TOKYO, Mar 25 (Pulse News Wire) – AnGes,Inc. (4563.T) announced the initiation of a clinical trial aimed at preventing acute ischemic brain damage in patients undergoing regular dialysis.
The trial, involving the drug candidate AV-001, received approval from Health Canada and is funded by the Heart and Stroke Foundation. The study, led by Christopher McIntyre, Professor at Western Daigaku, marks the first administration of AV-001 to a patient. AV-001 targets the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage and inflammation, addressing the unique vulnerability of dialysis patients to repetitive cerebral hypoxia.
This novel approach could redefine methods for protecting brain health in dialysis patients and contribute to larger validation trials, potentially improving quality of life and functionality in this high-risk population. The trial's positive outcomes may inform future studies and enhance treatment strategies for chronic kidney disease-related complications. AnGes, founded in 1,999 December, focuses on developing gene therapy drugs, with its lead product receiving breakthrough therapy designation from the US FDA in 2024.
Additionally, the company is advancing research on AV-001 for viral and bacterial pneumonia and NF-κB decoy oligonucleotide for chronic discogenic low back pain.
🟢 Confidence: High AI-translated content.